Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics
European Journal of Cancer · 2025-01 · 215 · 115169
DOI: 10.1016/j.ejca.2024.115169 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Cancer, 2025-01. Verfasst von Stanislas Quesada und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Institut régional du Cancer de Montpellier (ICM), Montpellier, France; Department of Cancer Genetics, University Hosp…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Consensus, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
BACKGROUND: Poly (ADP ribose) polymerase inhibitors (PARPis) are a treatment option for patients with advanced high-grade serous or endometrioid ovarian carcinoma (OC). Recent guidelines have clarified how homologous recombination deficiency (HRD) may influence treatment decision-making in this setting. As a result, numerous companion diagnostic assays (CDx) have been developed to identify HRD. However, the optimal HRD testing strategy is an area of debate. Moreover, recently published clinical and translational data may impact how HRD status may be used to identify patients likely to benefit from PARPi use. We aimed to extensively compare available HRD CDx and establish a worldwide expert consensus on HRD testing in primary and recurrent OC. METHODS: A group of 99 global experts from 31 different countries was formed. Using a modified Delphi process, the experts aimed to establish consensus statements based on a systematic literature search and CDx information sought from investigators, companies and/or publications. RESULTS: Technical information, including analytical and clinical validation, were obtained from 14 of 15 available HRD CDx (7 academic; 7 commercial). Consensus was reached on 36 statements encompassing the following topics: 1) the predictive impact of HRD status on PARPi use in primary and recurrent OC; 2) analytical and clinical validation requirements of HRD CDx; 3) resource-stratified HRD testing; and 4) how future CDx may include additional approaches to help address unmet testing needs. CONCLUSION: This manuscript provides detailed information on currently available HRD CDx and up-to-date guidance from global experts on HRD testing in patients with primary and recurrent OC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Institut régional du Cancer de Montpellier (ICM), Montpellier, France; Department of Cancer Genetics, University Hospital of Montpellier, Montpellier, France; Groupe d'Investigateurs Nati…
- Société Française de Médecine Prédictive et Personnalisée (SFMPP), Montpellier, France; Department of Biology and Pathology, Centre de Lutte Contre le Cancer Jean Perrin, Imagerie Moléculaire et Stratégies Théranostique…
- Department of Pathology, Hospital Universitari Arnau de Vilanova, IRBLLEIDA, University of Lleida, Lleida, Spain; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona,…
- The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
- Division of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
- Texas Oncology, US Oncology Network, The Woodlands, TX, USA.
Förderung
- AstraZeneca
Zitieren
APA
Quesada, S., Penault-Llorca, F., Matias-Guiu, X., Banerjee, S., Barberis, M., Coleman, R. L., Colombo, N., DeFazio, A., McNeish, I. A., Nogueira-Rodrigues, A., Oaknin, A., Pignata, S., Pujade-Lauraine, É., Rouleau, É., Ryška, A., Van Der Merwe, N., Van Gorp, T., Vergote, I., Weichert, W., …, & expert consensus group (2025). Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics. European Journal of Cancer, 215, 115169. https://doi.org/10.1016/j.ejca.2024.115169
Vancouver
Quesada S, Penault-Llorca F, Matias-Guiu X, Banerjee S, Barberis M, Coleman RL, et al. Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics. European Journal of Cancer. 2025;215:115169. doi:10.1016/j.ejca.2024.115169
BibTeX
@article{Quesada2025,
author = {Quesada, Stanislas and Penault-Llorca, Frédérique and Matias-Guiu, Xavier and Banerjee, Susana and Barberis, Massimo and Coleman, Robert L and Colombo, Nicoletta and DeFazio, Anna and McNeish, Iain A and Nogueira-Rodrigues, Angélica and Oaknin, Ana and Pignata, Sandro and Pujade-Lauraine, Éric and Rouleau, Étienne and Ryška, Aleš and Van Der Merwe, Nerina and Van Gorp, Toon and Vergote, Ignace and Weichert, Wilko and Wu, Xiaohua and Ray-Coquard, Isabelle and Pujol, Pascal and expert consensus group, expert consensus group},
title = {Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics},
journal = {European Journal of Cancer},
year = {2025},
volume = {215},
pages = {115169},
doi = {10.1016/j.ejca.2024.115169}
}
EUVIMED